Younes Maged, Aggett Peter, Aguilar Fernando, Crebelli Riccardo, Dusemund Birgit, Filipič Metka, Frutos Maria Jose, Galtier Pierre, Gundert-Remy Ursula, Kuhnle Gunter Georg, Lambré Claude, Leblanc Jean-Charles, Lillegaard Inger Therese, Moldeus Peter, Mortensen Alicja, Oskarsson Agneta, Stankovic Ivan, Waalkens-Berendsen Ine, Woutersen Rudolf Antonius, Wright Matthew, McArdle Harry, Tobback Paul, Pizzo Fabiola, Rincon Ana, Smeraldi Camilla, Gott David
EFSA J. 2018 Jun 6;16(6):e05291. doi: 10.2903/j.efsa.2018.5291. eCollection 2018 Jun.
The present scientific opinion deals with the evaluation of the safety of di-calcium malate (DCM) proposed as a novel food ingredient and as a source of calcium for use in foods for the general population, food supplements, total diet replacement for weight control and food for special medical purposes (FSMP), and with the bioavailability of calcium from this source. The structural formula of the proposed complex is based on expert judgement and not supported by any analytical data. On the basis of the available data, the Panel concluded that there was insufficient scientific evidence of a difference between the proposed novel food ingredient named as di-calcium malate (DCM) and calcium malate already authorised as a source of calcium included in Annex II to Directive 2002/46/EC. Accordingly, the Panel was unable to assess the safety of DCM as a novel food ingredient. On the basis of the results provided, the Panel considered that DCM does not completely dissociate into calcium and malic acid. The Panel concluded that when DCM dissociates, calcium would be available following ingestion of DCM and the bioavailability would appear similar to values reported for other sources of calcium already permitted. Furthermore, the Panel concluded that on the basis of the information available it was not possible to calculate the exposure to DCM as a source of calcium to foods for the general population, food supplements, total diet replacement for weight control and FSMP.
本科学意见涉及对提议作为新型食品成分以及作为钙源用于一般人群食品、食品补充剂、用于体重控制的全膳食替代物和特殊医学用途食品(FSMP)中苹果酸二钙(DCM)安全性的评估,以及该来源钙的生物利用度。提议的复合物的结构式基于专家判断,未得到任何分析数据的支持。根据现有数据,专家小组得出结论,没有足够的科学证据表明提议的名为苹果酸二钙(DCM)的新型食品成分与已被授权作为欧盟理事会2002/46/EC号指令附件II中钙源的苹果酸钙之间存在差异。因此,专家小组无法评估DCM作为新型食品成分的安全性。根据提供的结果,专家小组认为DCM不会完全解离为钙和苹果酸。专家小组得出结论,当DCM解离时,摄入DCM后钙将可用,且生物利用度似乎与已获许可的其他钙源所报告的值相似。此外,专家小组得出结论,根据现有信息,无法计算一般人群食品、食品补充剂、用于体重控制的全膳食替代物和FSMP中作为钙源的DCM的暴露量。